Filippo Acconcia
Overview
Explore the profile of Filippo Acconcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiocchetti M, Raimondi S, Bastari G, Bartoloni S, Marino M, Acconcia F
J Cell Biochem
. 2024 Jun;
125(7):e30610.
PMID: 38860517
17β-estradiol is a hormone that plays a vital role in human physiology. It acts through estrogen receptors, specifically estrogen receptor α and estrogen receptor β, and its action is determined...
2.
Bartoloni S, Pescatori S, Bianchi F, Cipolletti M, Acconcia F
Sci Rep
. 2024 Apr;
14(1):8200.
PMID: 38589728
Breast cancer (BC) is a leading cause of global cancer-related mortality in women, necessitating accurate tumor classification for timely intervention. Molecular and histological factors, including PAM50 classification, estrogen receptor α...
3.
PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells
Cipolletti M, Acconcia F
Mol Cell Endocrinol
. 2024 Jan;
584:112160.
PMID: 38266771
Purpose: Metabolic reprogramming in breast cancer (BC) subtypes offers potential personalized treatment targets. Estrogen receptor α (ERα)-positive BC patients undergoing endocrine therapy (ET) can develop ET-resistant metastatic disease. Specific mutations,...
4.
Franza M, Albanesi J, Mancini B, Pennisi R, Leone S, Acconcia F, et al.
Biochem Pharmacol
. 2023 Jul;
214:115675.
PMID: 37406967
Acute promyelocytic leukemia (APL) is a hematological disease characterized by the expression of the oncogenic fusion protein PML-RARα. The current treatment approach for APL involves differentiation therapy using all-trans retinoic...
5.
Cipolletti M, Leone S, Bartoloni S, Acconcia F
Front Endocrinol (Lausanne)
. 2023 May;
14:1129162.
PMID: 37143728
Targeting tumor cell metabolism is a new frontier in cancer management. Thus, metabolic pathway inhibitors could be used as anti-estrogen receptor α (ERα) breast cancer (BC) drugs. Here, the interplay...
6.
Montalesi E, Cracco P, Acconcia F, Fiocchetti M, Iucci G, Battocchio C, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768470
Breast cancer is the first leading tumor in women in terms of incidence worldwide. Seventy percent of cases are estrogen receptor (ER) α-positive. In these malignancies, 17β-estradiol (E2) via ERα...
7.
Leclercq G, Acconcia F
Front Endocrinol (Lausanne)
. 2023 Jan;
13:1094711.
PMID: 36619544
No abstract available.
8.
Pallottini V, Segatto M, Acconcia F, Fiocchetti M, Marino M
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555447
Naringenin (Nar) is one of major citrus flavonoids predominantly found in grapefruit and orange. In vivo studies have demonstrated Nar potential as a normolipidemic agent capable to reduce circulating cholesterol...
9.
Acconcia F
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232400
The molecular classification of breast cancer (BC) dictates pharmacological treatment. Estrogen receptor α (ERα) expressing tumors are treated with 4OH-tamoxifen or fulvestrant, which inhibits the receptor, or with aromatase inhibitors...
10.
Acconcia F
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142174
Breast cancer (BC) is the deadliest neoplastic disease for women worldwide [...].